Frailty as a determinant of mRNA vaccine efficacy
The Lancet Healthy Longevity · 2026-10 · 7 (10) · 100930
DOI: 10.1016/j.lanhl.2026.100930 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Lancet Healthy Longevity, 2026-10. Verfasst von Vishnu Vijay Vijayan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Dalhousie University, Halifax, NS, Canada; Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada. Hauptthemen laut MEDLINE: Vaccine Efficacy, Frailty, COVID-19 Vaccines, COVID-19. Die Arbeit nennt 156 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Lotte and John Hecht Memorial Foundation, Société canadienne du cancer, Heart and Stroke Foundation of Canada.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Frailty, an age-related state of increased vulnerability, is associated with greater susceptibility to infection and impaired vaccine response. In this Review, we examine how frailty-associated immunosenescence, including altered haematopoiesis, chronic inflammation, and dysfunction of innate and adaptive immune responses, can affect the immunogenicity, efficacy, and safety of lipid nanoparticle mRNA vaccines. Evidence from COVID-19 lipid nanoparticle mRNA vaccines and other vaccines suggests that people living with frailty can mount weaker or less durable responses than non-frail peers, although findings remain heterogeneous and frailty-specific evidence is scarce. The high customisability of lipid nanoparticle mRNA platforms creates opportunities for frailty-tailored vaccination. We discuss optimisation of lipid nanoparticle composition, targeting and dosing, mRNA cargo and combination-vaccine approaches, alongside host-directed measures addressing comorbidities, nutrition, and immune dysfunction. Integrating frailty into vaccine design, evaluation, and deployment could support safer, more effective, and more individualised vaccination strategies for older adults.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Dalhousie University, Halifax, NS, Canada; Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada.
- Department of Biochemistry & Molecular Biology, University of British Columbia, Vancouver, BC, Canada.
- Division of Geriatric Medicine, Department of Medicine, Dalhousie University, Halifax, NS, Canada; Department of Pharmacology, Dalhousie University, Halifax, NS, Canada.
- Division of Geriatric Medicine, Department of Medicine, Dalhousie University, Halifax, NS, Canada; Frailty and Elder Care Network, Nova Scotia Health, Halifax, NS, Canada.
- Department of Pathology, Dalhousie University, Halifax, NS, Canada; Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada; Department of Microbiology & Immunology, Dalhousie University, Halifax, NS, Canada; Dep…
Förderung
- Lotte and John Hecht Memorial Foundation
- Société canadienne du cancer
- Heart and Stroke Foundation of Canada
- Canadian Institutes of Health Research
- Research Nova Scotia
Zitieren
APA
Vijayan, V. V., Nair, P. G., Sheela, U. B., Cullis, P., Howlett, S. E., Rockwood, K., & Gujar, S. (2026). Frailty as a determinant of mRNA vaccine efficacy. The Lancet Healthy Longevity, 7(10), 100930. https://doi.org/10.1016/j.lanhl.2026.100930
Vancouver
Vijayan VV, Nair PG, Sheela UB, Cullis P, Howlett SE, Rockwood K, et al. Frailty as a determinant of mRNA vaccine efficacy. The Lancet Healthy Longevity. 2026;7(10):100930. doi:10.1016/j.lanhl.2026.100930
BibTeX
@article{Vijayan2026,
author = {Vijayan, Vishnu Vijay and Nair, Preethi Gopalakrishnan and Sheela, Unnikrishnan Babukuttan and Cullis, Pieter and Howlett, Susan E and Rockwood, Kenneth and Gujar, Shashi},
title = {Frailty as a determinant of mRNA vaccine efficacy},
journal = {The Lancet Healthy Longevity},
year = {2026},
volume = {7},
number = {10},
pages = {100930},
doi = {10.1016/j.lanhl.2026.100930}
}
EUVIMED